Project description
A platform for efficient collaboration on neurodegenerative disorders
An estimated 165 million Europeans are living with a brain disorder, including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. The Innovative Medicines Initiative, Europe’s biggest public and private collaboration in life sciences, has launched research projects to better understand and treat these disorders. To connect these projects, the EU-funded NEURONET project is developing a platform for mutual awareness and collaboration. It aims to help scientists identify gaps in research and make findings more visible. Among the project’s numerous goals is to map initiatives, assets and partnerships, assess impact, detect synergies and facilitate collaborations. Grounded on systems leadership approaches, it will detect opportunities for further research and transferable best practices that help accelerate future projects and make them more efficient.
Objective
The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide.
This will be achieved through the following specific objectives: 1) creation of an overall platform for efficient collaboration, communication and operational synergies among present and future IMI ND projects; 2) designing systems to map and analyse information regarding actions, initiatives and partnerships, assessing impact of the individual projects, remaining gaps and global value of the programme for stakeholders; 3) supporting the management of the programme (timelines, dependencies, synergies and key results across projects); 4) proactively detecting needs, opportunities and transferable best practices of projects and to connect them; 5) providing support to the projects by organising tools, services, expert advice and guidelines/recommendations on common issues; 6) promoting enhancement and coordination of communication across the IMI neurodegeneration projects, increasing programme visibility, outreaching to key stakeholders and establishing relationships with initiatives in the field; and 7) preparing and securing the long-term sustainability of NEURONET itself.
Achievement of these objectives will necessarily rely on buy-in from existing and future projects in the IMI ND portfolio, and effective connections with other programmes and initiatives in Europe and beyond, including stakeholder representation.
For this, the Consortium has been constituted by very active partners in a variety of IMI ND projects and related initiatives with specialists in areas like complex/project management, data sharing & re-use, drug development, patient engagement, communication, sustainability and regulatory/HTA interactions.
Fields of science
Keywords
Programme(s)
Funding Scheme
CSA - Coordination and support actionCoordinator
28006 Madrid
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.